An Observational, Prospective Cohort Study to Evaluate the Safety and Efficacy of Remsima in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)
Phase of Trial: Phase IV
Latest Information Update: 10 Jun 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Celltrion
- 05 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2019.
- 03 Jun 2015 Planned End Date changed from 1 Jun 2027 to 1 Jun 2026 as reported by ClinicalTrials.gov record.
- 01 Jan 2015 New trial record